B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of Arizona
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Incyte Corporation
Incyte Corporation
Fate Therapeutics
Brown University
SymBio Pharmaceuticals
Alliance for Clinical Trials in Oncology
University of California, Davis
Wake Forest University Health Sciences
Aptevo Therapeutics